Kodani Noriko, Ohsugi Mitsuru
Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.
Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Glob Health Med. 2022 Aug 31;4(4):210-215. doi: 10.35772/ghm.2022.01031.
Since December 2019, in the fight against the coronavirus disease 2019 (COVID-19) pandemic, we observed that glycemic control in people with diabetes is easily affected by lifestyle changes. To maintain a good health condition, a patient-centered approach with mental support and close monitoring is required. For these, telemedicine and online continuous glucose monitoring (CGM), are effective systems. Therefore, based on our experience during the two-year period, we reviewed the literature for appropriate actions required for the management of diabetes to prevent COVID-19 infection and avoid unfavorable outcomes in COVID-19 cases. Once infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a high risk of a poor prognosis in patients with diabetes. Glucocorticoid therapy in severe COVID-19 cases leads to further hyperglycemia. Since good glycemic control has been shown to improve outcomes, strict glycemic control using CGM is recommended. Using CGM data, insulin can be adequately titrated without causing hypoglycemia, and remote data monitoring can reduce the risk of infection for health care professionals, by reducing the frequency of patient contact. Among patients with COVID-19, some are found to have newly-diagnosed diabetes at admission. Those newly diagnosed patients present with a higher risk of poor prognosis compared to those with pre-existing diabetes. Therefore, glycemic status should be evaluated in all patients with COVID-19 admitted to hospitals.
自2019年12月以来,在抗击2019冠状病毒病(COVID-19)大流行的过程中,我们观察到糖尿病患者的血糖控制很容易受到生活方式改变的影响。为保持良好的健康状况,需要一种以患者为中心并提供心理支持和密切监测的方法。对于这些需求,远程医疗和在线连续血糖监测(CGM)是有效的系统。因此,基于我们两年来的经验,我们查阅了文献,以了解糖尿病管理所需的适当措施,以预防COVID-19感染,并避免COVID-19病例出现不良后果。一旦感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2),糖尿病患者预后不良的风险很高。重症COVID-19病例中的糖皮质激素治疗会导致血糖进一步升高。由于良好的血糖控制已被证明可改善预后,因此建议使用CGM进行严格的血糖控制。利用CGM数据,可以在不引起低血糖的情况下充分调整胰岛素剂量,并且远程数据监测可以通过减少与患者的接触频率来降低医护人员的感染风险。在COVID-19患者中,有些在入院时被发现患有新诊断的糖尿病。与患有糖尿病的患者相比,那些新诊断的患者预后不良的风险更高。因此,应对所有入院的COVID-19患者进行血糖状况评估。